: iStockAnalyst.com Symbols Feed

Diabetes Care: Global Investing Opportunities

Mon, 23 Nov 2009 03:23:59 GMT

The American Diabetes Association estimates that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billion in costs from diagnosed cases of diabetes in the U.S. (2007).[More...]

Hi-Tech Pharmacal: Hi-Growth at a Value Price

Wed, 28 Jan 2009 18:05:00 GMT

With shares of Home Diagnostics (HDIX) surging by nearly 50% since I profiled the company in mid-December as a turnaround, value play from the ETF Innovators Healthcare Cost Containment Index; a search for compelling values among these companies today led me to generic drug maker Hi-Tech[More...]

New Preventive Medicine Index

Sun, 25 Jan 2009 18:49:00 GMT

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies[More...]

CombiMatrix: Array Of Sunshine In '09?

Thu, 15 Jan 2009 14:08:00 GMT

The accompanying table (click to enlarge) includes statistics for all 40 companies included in the ETF Innovators Emerging Diagnostics Index of stocks with market caps of less than $150M and an average market value of $50M. The index has lost nearly 54% of its value in the past year, compared to declines of about 40% each for the S&P 500 SPDR ETF (SPY) + iShares Russell Micro-Cap ETF (IWC), 29% for the Healthcare Sector SPDR (XLV), and 15% for the SPDR S&P Biotech ETF (XBI).[More...]

A New Emerging Diagnostics Index

Fri, 26 Dec 2008 15:27:00 GMT

The accompanying table (click to enlarge) includes 39 companies in the ETF Innovators (ETFI) Emerging Diagnostics Index of U.S.-listed stocks with market caps of $10-$200M. The index includes diabetes care device makers such as DexCom (DXCM), personalized medicine lab service providers such as Clarient (CLRT), clinical diagnostic test developers such as OraSure (OSUR), diagnostic imaging service providers such as Virtual Radiologic (VRAD), diagnostic equipment makers such as Vision Sciences (VSCI), and genetic[More...]

Home Diagnostics Offers Value To Diabetics and Investors

Mon, 15 Dec 2008 18:47:00 GMT

With good returns so far since I profiled Caraco Pharma (CPD) as a defensive growth stock at a value price, a related company in the ETF Innovators (ETFI) Global Healthcare Cost Containment Index with similar value parameters is Home Diagnostics (HDIX) – which makes affordable[More...]

Generic Cardio Drugs Equal Brands

Tue, 02 Dec 2008 22:24:00 GMT

A meta-analysis review of clinical studies published in peer-reviewed journals was featured today in The Journal of the American Medical Association (JAMA) and concluded that cost-saving generics used to treat a variety of cardiovascular conditions produced equivalent clinical outcomes to higher cost brand name drugs. Despite this clinical evidence, the review notes that a majority (53%) of the 43 editorials analyzed had a negative opinion on generic substitution. While there are currently no ETFs on the market which feature generic drug companies, the ETF Innovators (ETFI)[More...]

A New Index of Healthcare Cost Containment Companies

Thu, 20 Nov 2008 04:33:00 GMT

The ETF Innovators (ETFI) Global Healthcare Cost Containment Index profiled in the accompanying table includes companies with market caps over $250M which are involved in the following two segments of the healthcare sector with the common theme of reducing healthcare costs and insurance premiums for consumers, employers, and third-party payers such as the government (through Medicare recipients) and insurance companies. Generic Healthcare Products: This category includes [More...]

Ten Under The Radar Small And Micro-Cap Value Stocks (Healthcare)

Sun, 16 Nov 2008 18:15:00 GMT

The accompanying table presents 10 small and micro-cap companies from a variety of industries which are trading at value parameters, with average valuations for the group of 0.54X trailing 12-month sales, 0.44X enterprise value to sales, 0.88X book value, and 8.7X trailing 12-month earnings. The iShares Russell 2000 Small-Cap Value ETF (IWN) has lost about 39% in the past year and serves as a useful ETF benchmark comparison for these companies. Healthcare – Diagnostics: Home Diagnostics (HDIX) is a maker of blood glucose monitoring systems and supplies under the TRUE and Prestige[More...]

Analyst Comments: Alexza Pharma, Joy Global, Kookmin Bank, MEMC Electronic Materials, Home Diagnostics

Thu, 04 Sep 2008 18:44:00 GMT

We are enthusiastic on Alexza Pharmaceuticals, Inc.?s (ALXA) proprietary novel Staccato system that reformulates oral or injectable small molecule compounds into an inhalable aerosol.? The development pipeline is moving forward nicely in our view.? The recent positive phase III data on AZ-004 is a significant milestone for the company. Alexza has six product candidates in clinical stage trials; including leading candidates AZ-001 for migraine headache pain relief and AZ-004 for acute agitation in patients with schizophrenia. Recent data on both drugs lead us to believe the Staccato system is both safe and highly effective.? By 2011 both AZ-001 and AZ-004 could be on the market, or at least under regulatory review. At this time we think investors can be patient with Alexza. Data on AZ-001 and AZ-004 looks encouraging, but the company[More...]

Home Diagnostics Reports Third Quarter 2009 Financial Results

Thu, 05 Nov 2009 11:47:00 GMT

Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced financial results for the third quarter ended September 30, 2009.
Gross profit for the third quarter of 2009 was $17.9 million, compared to $21.6 million in the third quarter of 2008.
Selling, general and administrative expenses were $11.6 million for the third quarter of 2009, compared with $13.4 million in the third quarter of 2008.

[More...]

The Home Diagnostics TRUE Family of Products Make Diabetes Testing More Affordable

Thu, 06 Aug 2009 13:06:00 GMT

American Association of Diabetes Educators (AADE) 36th Annual Meeting, Booth #126 - Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, is making diabetes testing more affordable with its low cost TRUE family of products. As people continue to struggle to make ends meet, diabetes patients also face the recurring cost of testing supplies, including test strips and meters. As store branded glucose monitoring systems, the TRUE family of products from Home Diagnostics costs significantly less than the national brands.[More...]

Home Diagnostics Reports Second Quarter 2009 Financial Results

Thu, 06 Aug 2009 11:53:00 GMT

Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced financial results for the second quarter ended June 30, 2009.
Gross profit for the second quarter of 2009 was $17.3 million, compared to $19.9 million in the second quarter of 2008.
On a sequential basis, second quarter 2009 gross margin improved 590 basis points from 47.1% in the first quarter 2009 as a result of improved yields on the TRUEtest manufacturing line and increased test strip volume.

[More...]

Home Diagnostics to Report Second Quarter 2009 Financial Results on August 6, 2009

Thu, 23 Jul 2009 12:27:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced details relating to its second quarter 2009 earnings announcement, which will take place before the market opens on Thursday, August 6, 2009.[More...]

Home Diagnostics Added to Russell Indexes

Wed, 01 Jul 2009 22:10:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that it has been added to the Russell 3000®, Russell 2000® and Russell Global Indexes, effective as of June 26, 2009 after the close of the U.S. markets.
"We welcome the addition of Home Diagnostics to the Russell Indexes," said Joe Capper, President and CEO of Home Diagnostics.
The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization.

[More...]

Home Diagnostics Launches TRUEmanager Diabetes Management Software

Wed, 24 Jun 2009 20:57:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced the launch of TRUEmanager™ Diabetes Management Software. The advanced reporting features and new user-friendly interface of TRUEmanager make it an essential tool for diabetes patients and healthcare professionals seeking long-term disease management.[More...]

Home Diagnostics to Present at Noble Financial Fifth Annual Equity Conference

Thu, 04 Jun 2009 21:55:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that Ronald Rubin, Chief Financial Officer of Home Diagnostics, is scheduled to present at the Noble Financial Fifth Annual Equity Conference at the Seminole Hard Rock Hotel and Casino in Hollywood, FL, on Monday, June 8, 2009, at 3:05 p.m. ET.[More...]

Home Diagnostics to Present at Deutsche Bank 34th Annual Health Care Conference

Wed, 13 May 2009 20:56:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that Joseph Capper, President and Chief Executive Officer, and Ronald Rubin, Chief Financial Officer, of Home Diagnostics are scheduled to present at the Deutsche Bank 34th Annual Health Care Conference at the InterContinental Boston Hotel on Tuesday, May 19, 2009, at 3:15 p.m. ET.[More...]

Home Diagnostics Reports First Quarter 2009 Financial Results

Thu, 07 May 2009 11:38:00 GMT

Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced financial results for the first quarter ended March 31, 2009.[More...]

Home Diagnostics to Present at Canaccord Adams Diabetes and Obesity Conference

Wed, 06 May 2009 20:56:00 GMT

Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that Joseph Capper, President and Chief Executive Officer, and Ronald Rubin, Chief Financial Officer, of Home Diagnostics are scheduled to present at the Canaccord Adams Diabetes and Obesity Conference at the InterContinental Barclay Hotel in New York, NY on Tuesday, May 12, 2009, at 2:40 p.m. ET.[More...]